Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 6/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 5/20 | 0.44 |
| ▸ | RAF1 | P04049 | 3/20 | 0.44 |
| ▸ | LYN | P07948 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831934 | 0.90 | CSF1R (0.66) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL7825726 | 0.90 | CSF1R (0.52) | CSF1RMAPK14MAPTBRAFRAF1 | |
| SCHEMBL7827478 | 0.86 | CSF1R (0.52) | CSF1RMAPK14MAPTBRAFRAF1 | |
| SCHEMBL7823001 | 0.85 | CSF1R (0.45) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL4824273 | 0.80 | BRAF (0.65) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL7825175 | 0.80 | MAPK14 (0.48) | MAPK14ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL7822467 | 0.79 | BRAF (0.54) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL7848504 | 0.78 | CSF1R (0.64) | CSF1RMAPK14ALDH1A1MAPTBRAF | |
| SCHEMBL4827733 | 0.76 | CSF1R (0.65) | CSF1RMAPK14BRAFRAF1LYN | |
| SCHEMBL4829551 | 0.76 | CSF1R (0.56) | CSF1RMAPK14BRAFRAF1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| EP-1163237-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055153-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | CSF1R 873/4885MAPK14 2834/4885ALDH1A1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.